Susan J. Schniepp - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Susan J. Schniepp


Susan J. Schniepp is a Pharmtech editorial advisory board (EAB) member

Susan J. Schniepp
Vice-President, Quality Assurance, Javelin Pharmaceuticals

Susan Schniepp has more than 28 years of experience in quality assurance for both the food and pharmaceutical industries. She has a degree in microbiology from Northern Illinois University and began her career in 1980 as a microbiologist in the food industry for Quaker Oats and M&M/Mars. In 1984, she began working for Searle Pharmaceuticals, and in 2000 she began working for Abbott Laboratories. In 2007, she formed her own consulting firm specializing in training, quality systems, technical writing, and standards interpretations. During her career in industry she had responsibilities for complaints, labeling, validation, documentation, and other quality systems, with a primary focus on establishing communications with compendial authorities.

Schniepp joined PDA in 2000 when she began working for Abbott Laboratories. She has presented at a number of PDA meetings and participated on a number of committees including the Joint Regulatory Conference Steering Committee, RAQC, Program Advisory Board, Technical Books Advisory Board, and The Membership Committee. In 2007, she was the recipient of PDA’s Distinguished Author Award for Understanding the United States Pharmacopeia and the National Formulary: Demystifying the Standards-Setting Process.

In addition to her PDA activities, Schniepp is chair of USP’s Monograph Development – Psychiatrics and Psychoactives Expert Committee for the 2005–2010 revision cycle, in addition to serving on the Council of Experts Executive Committee from 2005–2007. She is active in the Generic Pharmaceutical Association and founded both the Midwest and Western Compendial Discussion Groups.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
14%
Less restrictive inventory control by pharmaceutical companies
9%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here